Interpace Biosciences is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics. Since the company’s founding, it has helped physicians diagnose and treat more than 75,000 patients and have contributed to many of the most pivotal clinical trials in the pharmaceutical and biotech industries.
Interpace Diagnostics is a fully integrated commercial and bioinformatics company that provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services. It develops and commercializes molecular diagnostic tests that deliver cutting-edge genetic and mutational analysis. Its tests help risk-stratify patient samples for thyroid, pancreatic, lung, and other cancers to better inform treatment decisions.
For pharmaceutical and biotech companies engaged in oncology-focused clinical trials, Interpace Pharma Solutions offers a comprehensive testing portfolio that can help better select candidate populations and reduce adverse drug reactions. It provides seamless and dynamic coupling of comprehensive project life cycle management and full logistical support with the power of tested platforms for biomarker analysis, anatomic pathology, cytogenetics, and highly customized molecular technologies. Interpace Pharma Solutions has deep knowledge and experience in designing, developing, and validating assays with biomarkers of clinical relevance for cancer diagnosis, prognosis, and theranosis.